102 related articles for article (PubMed ID: 27473655)
1. In vitro selection of bispecific diabody fragments using covalent bicistronic DNA display.
Nakayama M; Komiya S; Fujiwara K; Horisawa K; Doi N
Biochem Biophys Res Commun; 2016 Sep; 478(2):606-11. PubMed ID: 27473655
[TBL] [Abstract][Full Text] [Related]
2. Phage diabody repertoires for selection of large numbers of bispecific antibody fragments.
McGuinness BT; Walter G; FitzGerald K; Schuler P; Mahoney W; Duncan AR; Hoogenboom HR
Nat Biotechnol; 1996 Sep; 14(9):1149-54. PubMed ID: 9631069
[TBL] [Abstract][Full Text] [Related]
3. Remodeling domain interfaces to enhance heterodimer formation.
Zhu Z; Presta LG; Zapata G; Carter P
Protein Sci; 1997 Apr; 6(4):781-8. PubMed ID: 9098887
[TBL] [Abstract][Full Text] [Related]
4. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics.
Kipriyanov SM; Moldenhauer G; Schuhmacher J; Cochlovius B; Von der Lieth CW; Matys ER; Little M
J Mol Biol; 1999 Oct; 293(1):41-56. PubMed ID: 10512714
[TBL] [Abstract][Full Text] [Related]
5. Improved tumour targeting by disulphide stabilized diabodies expressed in Pichia pastoris.
FitzGerald K; Holliger P; Winter G
Protein Eng; 1997 Oct; 10(10):1221-5. PubMed ID: 9488147
[TBL] [Abstract][Full Text] [Related]
6. Disulfide-stabilized diabody antiCD19/antiCD3 exceeds its parental antibody in tumor-targeting activity.
Wei L; Dongmei F; Ming Y; Ruizan S; Yan Y; Linlin J; Cihui Y; Shuangjing L; Min W; Jianxiang W; Dongsheng X
Cell Oncol (Dordr); 2012 Dec; 35(6):423-34. PubMed ID: 23055339
[TBL] [Abstract][Full Text] [Related]
7. Construction of a diabody (small recombinant bispecific antibody) using a refolding system.
Takemura S; Asano R; Tsumoto K; Ebara S; Sakurai N; Katayose Y; Kodama H; Yoshida H; Suzuki M; Imai K; Matsuno S; Kudo T; Kumagai I
Protein Eng; 2000 Aug; 13(8):583-8. PubMed ID: 10964988
[TBL] [Abstract][Full Text] [Related]
8. Anti-HLA-DR/anti-DOTA diabody construction in a modular gene design platform: bispecific antibodies for pretargeted radioimmunotherapy.
DeNardo DG; Xiong CY; Shi XB; DeNardo GL; DeNardo SJ
Cancer Biother Radiopharm; 2001 Dec; 16(6):525-35. PubMed ID: 11789029
[TBL] [Abstract][Full Text] [Related]
9. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
Nielsen UB; Adams GP; Weiner LM; Marks JD
Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
[TBL] [Abstract][Full Text] [Related]
10. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.
Bühler P; Wolf P; Gierschner D; Schaber I; Katzenwadel A; Schultze-Seemann W; Wetterauer U; Tacke M; Swamy M; Schamel WW; Elsässer-Beile U
Cancer Immunol Immunother; 2008 Jan; 57(1):43-52. PubMed ID: 17579857
[TBL] [Abstract][Full Text] [Related]
11. Development and characterization of an αvβ6-specific diabody and a disulfide-stabilized αvβ6-specific cys-diabody.
White JB; Boucher DL; Zettlitz KA; Wu AM; Sutcliffe JL
Nucl Med Biol; 2015 Dec; 42(12):945-57. PubMed ID: 26341848
[TBL] [Abstract][Full Text] [Related]
12. Acquired antagonistic activity of a bispecific diabody directed against two different epitopes on vascular endothelial growth factor receptor 2.
Lu D; Kotanides H; Jimenez X; Zhou Q; Persaud K; Bohlen P; Witte L; Zhu Z
J Immunol Methods; 1999 Nov; 230(1-2):159-71. PubMed ID: 10594363
[TBL] [Abstract][Full Text] [Related]
13. Structural diversity and flexibility of diabodies.
Kwon NY; Kim Y; Lee JO
Methods; 2019 Feb; 154():136-142. PubMed ID: 30261312
[TBL] [Abstract][Full Text] [Related]
14. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
[TBL] [Abstract][Full Text] [Related]
15. [Construction and expression of disulphide stabilized anti-CD3/anti-Pgp diabody].
Su Y; Liu J; Gao Y; Qin L; Yang M; Wang J; Xu Y; Shao X; Ji Q; Xiong D; Yang C
Sheng Wu Gong Cheng Xue Bao; 2009 Jul; 25(7):1042-8. PubMed ID: 19835146
[TBL] [Abstract][Full Text] [Related]
16. Complement recruitment using bispecific diabodies.
Kontermann RE; Wing MG; Winter G
Nat Biotechnol; 1997 Jul; 15(7):629-31. PubMed ID: 9219263
[TBL] [Abstract][Full Text] [Related]
17. Retargeting serum immunoglobulin with bispecific diabodies.
Holliger P; Wing M; Pound JD; Bohlen H; Winter G
Nat Biotechnol; 1997 Jul; 15(7):632-6. PubMed ID: 9219264
[TBL] [Abstract][Full Text] [Related]
18. Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody.
Holliger P; Brissinck J; Williams RL; Thielemans K; Winter G
Protein Eng; 1996 Mar; 9(3):299-305. PubMed ID: 8736497
[TBL] [Abstract][Full Text] [Related]
19. Enzyme immunoassays using bispecific diabodies.
Kontermann RE; Martineau P; Cummings CE; Karpas A; Allen D; Derbyshire E; Winter G
Immunotechnology; 1997 Jun; 3(2):137-44. PubMed ID: 9237098
[TBL] [Abstract][Full Text] [Related]
20. Improvement of tumor targeting and antitumor activity by a disulphide bond stabilized diabody expressed in Escherichia coli.
Liu J; Yang M; Wang J; Xu Y; Wang Y; Shao X; Yang C; Gao Y; Xiong D
Cancer Immunol Immunother; 2009 Nov; 58(11):1761-9. PubMed ID: 19259665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
